Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-387, an investigational, that is in Phase 2/3 clinical trial for human immunoglobulin G2 monoclonal antibody that binds human interleukin-1 receptor 1, inhibiting IL-1a, IL-1ß-mediated signaling for the treatment of advance recurrent pericarditis by providing the added convenience of monthly subcutaneous dosing with a liquid formulation. Its preclinical products include KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024. The company was incorporated in 2015 and is based in London, the United Kingdom.

Period	Debt/Equity
2018-12-31	0.15
2019-12-31	0.13
2020-12-31	0.12
2021-12-31	0.26
2022-12-31	0.16
2023-12-31	0.20
2024-12-31	0.32

	A	B	C	D
1	Symbol	Price	Change	Volume
2	KNSA	$47.05	-3.87%	0.44M
3
4
5

Kiniksa Pharmaceuticals Ltd. (KNSA) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Kiniksa Pharmaceuticals Ltd. Data in Excel

More KNSA Financial Data